EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Piper Sandler 35th Annual Healthcare Conference – Presentation
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
- Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα expression – - Safety profile was consistent with prior data in...
14th Annual World ADC Conference – Presentations and Poster
Development of Next Generation ADCs Using Novel Expression Platforms & Precise ConjugationPresenter: Gang YinDiscovery of Novel Linker Payloads for Site-Specific ADCs with Improved Efficacy & Therapeutic IndexPresenter: Krishna BajjuriPrecision Engineering for...
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., October 16, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the company will have five...
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., August 30, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
2023 American Society of Clinical Oncology (ASCO) Annual Meeting – Presentation
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient...
Sutro Biopharma to Participate in the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), todayannounced that Bill Newell, Chief Executive...
2023 American Society of Pediatric Hematology / Oncology (ASPHO) Annual Meeting – Poster
A Novel Therapy for Refractory CBFA2T3::GLIS2-associated AMKL Using STRO-002 And Plerixafor
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 8, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), todayannounced that Bill Newell, Chief Executive...